Protein Phosphatase 2A – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Protein Phosphatase 2A (PP2A or EC 3.1.3.16) – Pipeline Review, H1 2020’, provides in depth analysis on Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Metabolic Disorders, Ophthalmology and Respiratory under development targeting Protein Phosphatase 2A (PP2A or EC 3.1.3.16).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)

– The report reviews Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics and enlists all their major and minor projects

– The report assesses Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Protein Phosphatase 2A (PP2A or EC 3.1.3.16) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Lixte Biotechnology Holdings Inc

PEP-Therapy SAS

Re-Pharm Ltd

SupremeCure Pharma Inc

Velacor Therapeutics Pty Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Protein Phosphatase 2A (PP2A or EC

3.1.3.16) – Overview

Protein Phosphatase 2A (PP2A or EC

3.1.3.16) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Protein Phosphatase 2A (PP2A or EC

3.1.3.16) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Protein Phosphatase 2A (PP2A or EC

3.1.3.16) – Companies Involved in Therapeutics Development

Lixte Biotechnology Holdings Inc

PEP-Therapy SAS

Re-Pharm Ltd

SupremeCure Pharma Inc

Velacor Therapeutics Pty Ltd

Protein Phosphatase 2A (PP2A or EC

3.1.3.16) – Drug Profiles

LB-100 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEP-010 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-0217 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate PP2A for Castration Resistant Prostate Cancer and Lung Cancer – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PPP2R2A for Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-X – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VEL-015 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein Phosphatase 2A (PP2A or EC

3.1.3.16) – Dormant Products

Protein Phosphatase 2A (PP2A or EC

3.1.3.16) – Product Development Milestones

Featured News & Press Releases

Dec 04, 2019: First two patients enrolled in National Cancer Institute trial of the ability of Lixte Biotechnology’s LB-100 to enter recurrent malignant Brain Tumors

Aug 06, 2019: The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings’ LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas

Jul 18, 2019: First patient enrolled in phase 1b/2 trial of Lixte Biotechnology’s LB-100 in low or intermediate-1 Risk Myelodysplastic Syndrome

Jun 25, 2019: Lixte Biotechnology's PP2A inhibitor, LB-100, improves brain function and motor impairment in a mouse model of Angelman syndrome, a rare human neurodevelopmental disorder

May 16, 2019: PEP-Therapy reports positive results from GLP-Toxicity study of PEP-010 drug candidate

May 15, 2019: Lixte Biotechnology's LB-100 to be evaluated by the National Cancer Institute in a clinical study of LB-100's ability to enter recurrent Glioblastoma Multiforme brain tumors

Nov 05, 2018: FDA approves Lixte Biotechnology’s IND to conduct a phase 1b/2 trial of LB-100 in patients with myelodysplastic syndrome at Moffitt Cancer Center

Oct 09, 2018: Lixte Biotechnology files an IND with the FDA to conduct a phase 1b/2 trial of LB-100 in patients with myelodysplastic syndrome at Moffitt Cancer Center

Apr 17, 2018: PEP-Therapy, Institut Curie and Gustave Roussy Obtain 2,9 M€ to Develop a Novel Peptide in Oncology

Feb 09, 2018: LB-100, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitor, Sensitizes BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase Inhibitors

Jun 13, 2017: Re-Pharm and Cresset Discovery Services to attend BIO International for partnering

Apr 17, 2017: Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model

Mar 09, 2017: Late-Breaking Abstract on LB-100, Lixte Biotechnologys Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting

Jan 04, 2017: First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research

Nov 03, 2016: Re-Pharm to present at IDDST, Nanjing, China and available for one-to-one meetings

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Lixte Biotechnology Holdings Inc, H1 2020

Pipeline by PEP-Therapy SAS, H1 2020

Pipeline by Re-Pharm Ltd, H1 2020

Pipeline by SupremeCure Pharma Inc, H1 2020

Pipeline by Velacor Therapeutics Pty Ltd, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports